Welcome to our dedicated page for Aptose Bioscienc SEC filings (Ticker: APTOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aptose Biosciences Inc. (APTOF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian issuer reporting to the U.S. Securities and Exchange Commission. Aptose files current reports on Form 8-K under Commission File Number 001-32001, alongside its Canadian securities filings. These documents are central for investors who want to understand the company’s clinical-stage oncology business, financial condition, and pending corporate transactions.
For Aptose, Form 8-K filings are particularly important. Recent 8-Ks include Regulation FD disclosures that furnish press releases about tuspetinib (TUS) clinical data from the TUSCANY Phase 1/2 trial, including safety, complete remission (CR/CRh) rates, and minimal residual disease (MRD) findings in acute myeloid leukemia (AML). Other 8-Ks report quarterly financial results, detailing research and development expenses by program, general and administrative costs, cash balances, and the company’s reliance on loan facilities from Hanmi Pharmaceutical Co. Ltd. to fund operations.
Another critical category of filings relates to material definitive agreements and corporate transactions. Aptose has filed an 8-K describing its definitive arrangement agreement with Hanmi and HS North America Ltd., under which a Hanmi subsidiary will acquire all Aptose common shares not already owned or controlled by Hanmi or its affiliates, subject to shareholder and court approvals. That filing outlines the transaction structure, consideration for minority shareholders, required approvals, and the expectation that, after completion, Aptose will no longer be subject to certain reporting requirements and its shares will be delisted from stock exchanges including the TSX.
Through Stock Titan, investors can review these filings and use AI-powered summaries to interpret key sections, such as risk factor discussions, forward-looking statements, and the implications of financing and transaction agreements. The platform also tracks new 8-Ks in real time, helping users monitor Aptose’s ongoing clinical disclosures, financial updates, and progress toward the proposed acquisition.
Aptose Biosciences Inc. filed a current report to furnish information under Regulation FD. On September 22, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference. The company notes that this press release is being furnished under Item 7.01 of the Exchange Act and is not deemed “filed” for liability purposes under Section 18 or automatically incorporated into other securities law filings.